scholarly journals Examining race as a predictor and moderator of treatment outcomes for binge-eating disorder: Analysis of aggregated randomized controlled trials.

2019 ◽  
Vol 87 (6) ◽  
pp. 530-540 ◽  
Author(s):  
Janet A. Lydecker ◽  
Ralitza Gueorguieva ◽  
Robin Masheb ◽  
Marney A. White ◽  
Carlos M. Grilo
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Randomized Controlled Trials ◽  
Treatment Outcomes ◽  
Binge Eating Disorder ◽  
Controlled Trials ◽  
Randomized Controlled

Psychiatric comorbidity as predictor and moderator of binge-eating disorder treatment outcomes: an analysis of aggregated randomized controlled trials

2021 ◽  
pp. 1-9
Author(s):  
Janet A. Lydecker ◽  
Carlos M. Grilo
Keyword(s):  
Weight Loss ◽  
Eating Disorder ◽  
Binge Eating ◽  
Treatment Outcomes ◽  
Binge Eating Disorder ◽  
Psychiatric Comorbidity ◽  
Controlled Trials ◽  
Eating Frequency ◽  
Randomized Controlled ◽  
Eating Disorder Psychopathology

Abstract Background Psychiatric comorbidity is common in binge-eating disorder (BED) but effects on treatment outcomes are unknown. The current study aimed to determine whether psychiatric comorbidity predicted or moderated BED treatment outcomes. Methods In total, 636 adults with BED in randomized-controlled trials (RCTs) were assessed prior, throughout, and posttreatment by doctoral research-clinicians using reliably-administered semi-structured interviews, self-report measures, and measured weight. Data were aggregated from RCTs testing cognitive-behavioral therapy, behavioral weight loss, multi-modal (combined pharmacological plus cognitive-behavioral/behavioral), and/or control conditions. Intent-to-treat analyses (all available data) tested comorbidity (mood, anxiety, ‘any disorder’ separately) as predictors and moderators of outcomes. Mixed-effects models tested comorbidity effects on binge-eating frequency, global eating-disorder psychopathology, and weight. Generalized estimating equation models tested binge-eating remission (zero binge-eating episodes during the past month; missing data imputed as failure). Results Overall, 41% of patients had current psychiatric comorbidity; 22% had mood and 23% had anxiety disorders. Psychiatric comorbidity did not significantly moderate the outcomes of specific treatments. Psychiatric comorbidity predicted worse eating-disorder psychopathology and higher binge-eating frequency across all treatments and timepoints. Patients with mood comorbidity were significantly less likely to remit than those without mood disorders (30% v. 41%). Psychiatric comorbidity neither predicted nor moderated weight loss. Conclusions Psychiatric comorbidity was associated with more severe BED psychopathology throughout treatment but did not moderate outcomes. Findings highlight the need to improve treatments for BED with psychiatric comorbidities but challenge perspectives that combining existing psychological and pharmacological interventions is warranted. Treatment research must identify more effective interventions for BED overall and for patients with comorbidities.

scholarly journals Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials

2015 ◽  
Vol 41 (5) ◽  
pp. 1251-1260 ◽  
Author(s):  
Susan L McElroy ◽  
James Hudson ◽  
M Celeste Ferreira-Cornwell ◽  
Jana Radewonuk ◽  
Timothy Whitaker ◽  
...  
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Randomized Controlled Trials ◽  
Binge Eating Disorder ◽  
Controlled Trials ◽  
Phase 3 ◽  
Pivotal Phase ◽  
Lisdexamfetamine Dimesylate ◽  
Randomized Controlled

scholarly journals The efficacy of eHealth interventions in treating adults diagnosed with full and subthreshold binge eating disorder: A Meta-analysis (Preprint)

2020 ◽  
Author(s):  
Elnaz Moghimi ◽  
Caroline Davis ◽  
Michael Rotondi
Keyword(s):  
Eating Disorder ◽  
Binge Eating ◽  
Randomized Controlled Trials ◽  
Binge Eating Disorder ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Wait List ◽  
Randomized Controlled ◽  
Short Period ◽  
Significant Difference

BACKGROUND There has been a recent rise in the use of eHealth treatments for a variety of psychological disorders, including eating disorders. OBJECTIVE This meta-analysis of randomized controlled trials is the first to evaluate the efficacy of eHealth interventions specifically for the treatment of binge eating disorder (BED)– characterized by compulsive overconsumption of food, in a relatively short period of time and without compensatory behaviors like purging or fasting. METHODS A search on the electronic databases PubMed, Web of Science, Embase, Medline, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) was conducted for randomized controlled trials that compared the efficacy of eHealth treatment interventions to wait-list controls. From the databases searched, three studies met the inclusion criteria, and all the interventions administered were forms of internet-based guided cognitive behavioral therapy. RESULTS The results of the analysis demonstrate that when compared to wait list controls, eHealth interventions reduce objective binge episodes (OBE; SMD is -0.77, 95% CI, -1.38 to -0.16) and eating disorder psychopathology (SMD -0.71, 95% CI -1.20 to -0.22), which include shape (SMD -0.61, 95% CI -1.01 to -0.22) and weight concerns (SMD -0.91, 95% CI -1.33 to -0.48). There was no significant difference in body mass index between eHealth interventions and controls (SMD -0.01, 95% CI, -0.40 to 0.39). CONCLUSIONS These findings provide promising results for the use of internet-based CBT for BED treatment and support the greater need for future research to explore the efficacy of these eHealth interventions.

scholarly journals Topiramate: use in binge eating disorder?

2012 ◽  
pp. 282-287
Author(s):  
Mauro Gentile ◽  
Giovanni Scanelli
Keyword(s):  
Eating Disorder ◽  
Side Effects ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Search Strategy ◽  
Current Knowledge ◽  
Significant Weight Loss ◽  
Good Tool ◽  
Randomized Controlled ◽  
Treatment Of Diabetes

Introduction: Topiramate was serendipitously synthesized in 1979 during research aimed at developing a fructose-1,6-diphosphatase inhibitor that might be used in the treatment of diabetes mellitus. Some investigators have suggested it might be used in the treatment of binge eating disorder (BED). The aim of this review was to evaluate current knowledge and opinions on this topic. Materials and methods: We conducted a search of five electronic databases (PubMed, Embase, Nice, Cochrane, Cinahl) using the search strategy ‘‘topiramate’’ AND ‘‘binge’’, ‘‘binge eating disorder.’’ No time limits were applied, and only reports of randomized controlled trials were included in our analysis. Results: In clinical studies, topiramate use has been associated with significant weight loss mediated by reductions in the frequency of bingeing episodes. The most common side effects of the drug are paresthesias, but nephrolithiasis, oligohydrosis, and dizziness have also been described. Conclusions: Available data are limited, but the literature we reviewed suggests that topiramate can be useful in the medical treatment of BED, reducing both body weight and binge episodes. Side effects are not negligible. Before topiramate can be regarded as a good tool for the treatment of BED, further data must be obtained from longer, methodologically correct studies of larger populations.

Sign in / Sign up

Export Citation Format

Share Document